Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

作者：Madhusudan Kabra, Tristan Barber, Clotilde Allavena, Anne‐Geneviève Marcelin, Simona Di Giambenedetto, Juan Pasquau, Nicola Gianotti, Josep M. Llibre, David Rial‐Crestelo, Rosa de Miguel Buckley, Gary Blick, Matthew Turner, Cale Harrison, T. Wynne, Gustavo Verdier, Chris M. Parry, Bryn Jones, Chinyere Okoli, Cynthia Donovan, Julie Priest, Emílio Letang · 发表于：Open Forum Infectious Diseases · 年份：2023 · DOI：10.1093/ofid/ofad526 · 被引用次数：24 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、Hepatitis C virus research

Background: To investigate the impact of the M184V/I mutation on virologic response to dolutegravir plus lamivudine (DTG + 3TC) in suppressed-switch populations, a meta-analysis was performed using virologic outcomes from people with human immunodeficiency virus type 1 (PWH) with and without M184V/I before DTG + 3TC switch in real-world studies identified via systematic literature review. Sensitivity analyses were performed using data from PWH with M184V/I in interventional studies identified via targeted literature review. Methods: Single-arm meta-analyses using common- and random-effects models were used to estimate proportions of PWH with virologic failure (VF) among real-world populations with and without M184V/I and interventional study participants with M184V/I at 24, 48, and 96 weeks. Results: Literature reviews identified 5 real-world studies from 3907 publications and 51 abstracts meeting inclusion criteria and 5 interventional studies from 1789 publications and 3 abstracts. All time points had low VF incidence in PWH with M184V/I (real-world: 1.43%-3.81%; interventional: 0.00%) and without (real-world: 0.73%-2.37%). Meta-analysis-estimated proportions (95% confidence interval) with VF were low at weeks 24, 48, and 96, respectively, for PWH with M184V/I (real-world: 0.01 [.00-.04], 0.03 [.01-.06], and 0.04 [.01-.07]; interventional: 0.00 [.00-.02], 0.00 [.00-.01], and 0.00 [.00-.03]) and without (real-world: 0.00 [.00-.02], 0.02 [.01-.04], and 0.02 [.00-.05]). One re...